Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 8/20 | 0.59 |
| ▸ | HTR1B | P28222 | 6/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6817268 | 0.93 | HTR1D (0.61) | HTR1DHTR1BHTR2AHTR1AADRA1A | |
| SCHEMBL6817232 | 0.85 | HTR1D (0.67) | HTR1DHTR1BHTR2AHTR1ADRD2 | |
| SCHEMBL7803371 | 0.75 | HTR1D (1.00) | HTR1DHTR1BHTR2AHTR1ATMPRSS2 | |
| SCHEMBL9299684 | 0.73 | HTR1D (0.55) | HTR1DHTR1BHTR2AHTR1ADRD2 | |
| SCHEMBL6812001 | 0.73 | HTR1D (0.53) | HTR1DHTR1BHTR2AHTR1ADRD2 | |
| SCHEMBL8985970 | 0.73 | HTR1D (0.92) | HTR1DHTR1BHTR2AHTR1ATMPRSS2 | |
| SCHEMBL6812630 | 0.73 | HTR1D (0.48) | HTR1DHTR1BHTR2AHTR1ADRD2 | |
| SCHEMBL8400880 | 0.71 | HTR1D (0.79) | HTR1DHTR1BHTR2AHTR1AMAPT | |
| SCHEMBL9301655 | 0.70 | HTR1D (0.55) | HTR1DHTR1BHTR2AHTR1ATMPRSS2 | |
| SCHEMBL8302847 | 0.70 | HTR1D (0.59) | HTR1DHTR1BHTR2AHTR1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132742-A1 | Novel compounds | BROMIDGE STEVEN MARK (GB) | 2004-07-08 | — | — | US | claimed |
| US-20030144505-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2003-07-31 | — | — | US | claimed |
| US-20010051719-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2001-12-13 | — | — | US | claimed |
| EP-0946551-A2 | N-PIPERAZIN-1-YLPHENYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027058-A2 | N-PIPERAZIN-1-YLPHENYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | claimed |
| US-20040132742-A1 | Novel compounds | BROMIDGE STEVEN MARK (GB) | 2004-07-08 | — | — | US | disclosed |
| US-20030144505-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2003-07-31 | — | — | US | disclosed |
| US-20010051719-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2001-12-13 | — | — | US | disclosed |
| EP-0946551-A2 | N-PIPERAZIN-1-YLPHENYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027058-A2 | N-PIPERAZIN-1-YLPHENYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144505-A1 | Novel compounds | HTR1F, HTR6, HTR3C | HTR1D 5/4885HTR1B 9/4885HTR2A 35/4885 |
| US-20040132742-A1 | Novel compounds | CNR2, CNR1, ATP6V1B2 | HTR1D 146/4885HTR1B 91/4885HTR2A 77/4885 |
| US-20010051719-A1 | Novel compounds | CNR2, CNR1, ATP6V1B2 | HTR1D 284/4885HTR1B 157/4885HTR2A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.